title: Adenosine A2A-receptor blockade abolishes the roll-off respiratory response to hypoxia in awake lambs.
abstract: Adenosine (ADO) receptor antagonists (aminophylline, caffeine) blunt the respiratory roll-off response to hypoxia in the newborn. This study was designed to determine the ADO receptor subtype involved in the respiratory depression. Chronically catheterized lambs of 7-16 days of age breathed via face mask a gas mixture with a fraction of inspired O2 of 0.21 (normoxia) or 0.07 (hypoxia), while being infused intravascularly with 9-cyclopentyl-1,3-dipropylxanthine (DPCPX; ADO A1-receptor antagonist, n=8), ZM-241385 (ADO A2A-receptor antagonist, n=7), or vehicle. Ventilation was measured at 20 degrees C by a turbine transducer flowmeter. In normoxia [arterial Po2 (PaO2) of approximately 83 Torr], infusion of vehicle did not alter cardiorespiratory measurements, whereas hypoxia (PaO2 of approximately 31 Torr, 15 min) elicited biphasic effects on mean arterial pressure (transient increase), heart rate (HR; diminishing tachycardia), and minute ventilation. In the latter, hypoxia increased ventilation to a peak value of approximately 2.5 times control within the first 3 min, which was followed by a significant (P<0.05) decline to approximately 50% of the maximum increment over the subsequent 7 min. ZM-241385 abolished the hypoxic ventilatory roll-off and blunted the rate of rise in HR without affecting mean arterial pressure or rectal temperature responses. In normoxia, DPCPX increased ventilation and mean arterial pressure but did not change HR. Compared with vehicle, DPCPX did not significantly affect cardiorespiratory responses to hypoxemia (PaO2 of approximately 31 Torr, 10 min). It is concluded that 1) ADO A2A receptors are critically involved in the ventilatory roll-off and HR responses to hypoxia, and 2) ADO A1 receptors, which are tonically active in cardiorespiratory control in normoxia, appear to have little impact on hypoxic ventilatory depression.
authors.affiliation: Nicholas S. Assali Perinatal Research, Dept. of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1740, USA. bkoos@mednet.ucla.edu
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Koos
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kawasaki
authors.forename: Young-Han
authors.initials: YH
authors.lastname: Kim
authors.forename: Fanor
authors.initials: F
authors.lastname: Bohorquez
mesh_terms: D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001831:Body Temperature / Q000187:drug effects / Q000502:physiology; D002245:Carbon Dioxide / Q000097:blood; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006863:Hydrogen-Ion Concentration; D000860:Hypoxia / Q000503:physiopathology*; D010100:Oxygen / Q000097:blood; D043705:Receptor, Adenosine A2A / Q000502:physiology*; D012119:Respiration / Q000187:drug effects; D012756:Sheep; D013990:Tidal Volume / Q000187:drug effects / Q000502:physiology; D013997:Time Factors; D014227:Triazines / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
chemical_list: D058917:Adenosine A2 Receptor Antagonists; D043705:Receptor, Adenosine A2A; D014227:Triazines; D014230:Triazoles; D014970:Xanthines; C097270:ZM 241385; D002245:Carbon Dioxide; C051360:1,3-dipropyl-8-cyclopentylxanthine; D010100:Oxygen